Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
The Law Bytes Podcast, Episode 274: Mark Musselman on What Stakeholders Really Think About the Government’s Reversal of the CRTC Online Streaming Act Decision 
Improv Policy: The Government Doesn’t Know What To Do About Its Online Streaming Act Mess 
Soft Ban or Hard Verification Requirement?: Why Bill C-34’s Social Media Ban Exemption Gets the Incentives Wrong and Comes Too Late to Matter 
New Rights, New Powers, Long Delays: Bill C-36’s Seven-Step Process for Privacy Reform to Take Effect 
The Law Bytes Podcast, Episode 273: Rebroadcast of the Globe and Mail’s The Decibel on Canada’s First Steps Towards a Social Media Ban
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?